Articles On Proteomics International Laboratories (ASX:PIQ)

Proteomics International Laboratories has secured a key partner for the looming roll-out of its PromarkerD predictive test to fight kidney disease by signing an exclusive licence deal with Sonic Healthcare USA.

Proteomics International (PIQ) signs an exclusive licence agreement with Sonic Healthcare USA to commercialise PromarkerD in the US PromarkerD is a newly developed blood test able to predict a decline in kidney function in type two diabe...

The ASX 200 benchmark has posted a solid slab of gains, up 0.78% for the day Energy and Materials have teamed up to bring the winnings, at +2.5% and +1.6% respectively Creso Pharma’s buy-out of HHI delivers strong backing from investors, u...

ASX health stocks fall 0.8% in the past five days in line with broader markets following latest rate hike Investors rewarding health stocks with near term catalysts in 2023, including Neuren and Impedimed Health imaging stock Volpara recor...

Proteomics International Laboratories has strengthened its fight against kidney disease with the identification of a diabetes drug that has boosted the prospects of its PromarkerD predictive test.

Diabetes drug Canagliflozin lowers Proteomics’ PromarkerD diabetic prediction scores Artrya says Q-Submission (Q-Sub) has now been lodged with the FDA Universal Bio launched the PETRACKR blood glucose monitoring product for pets   Protemi...

The ASX will open lower this morning after a 1% fall on Wall Street US regional bank stocks tumbled again Oil prices crashed around 5% on recession fears   The ASX is poised to tumble on Wednesday, tracking the moves in New York. At 8am A...

ASX-listed Proteomics International Laboratories has beefed up its clinical advisory board ahead of the rollout of its Promarker D predictive test for diabetic kidney disease in type 2 diabetes patients.

Proteomics International Laboratories’ plans for the global launch of its PromarkerD test for predicting diabetic kidney disease have received a significant boost with the renewal of two key accreditations.

Proteomics is confident of finalising a deal with Sonic Healthcare to use its PromarkerD test in its US labs Promising results of new blood test show it could transform how endometriosis is diagnosed in women Morgans said a deal with Sonic...

ASX health stocks rise 0.97% in the past five days in line with broader markets Impedimed up 99% after BIS tech named in latest US NCCN guidelines for lymphoedema  EBR Systems to release top line results at cardiac conference Heart Rhythm...

Benchmark set to finish close to flat as Energy stocks slump again Goldies are surging again, with that sector up 1.3% for the day Even the big banks are bracing for trouble with talk of a crisis getting louder by the day   After a modera...

Proteomics International Laboratories says it has developed a simple new blood test to identify up to 90 per cent of patients with endometriosis, following a study of more than 900 participants.

ASX health stocks fall 1.5% in the past five days, broader markets fall on global banking concerns Neuren Pharmaceuticals has soared 60% after FDA approves its drug for Rett’s syndrome  Antisense starts chronic monkey toxicology study of A...

Proteomics International Laboratories (ASX:PIQ) has announced that it will resubmit its application to have the PromarkerD predictive test for diabetic kidney disease funded via Medicare.

ASX health stocks fall 1.87% in the past five days as reporting season ends Healius moves to a statutory loss of ~$29 million following reduced demand for Covid-19 testing Catalysts in next few months for several ASX health stocks which co...

Tony Locantro, Alto Capital BUY RECOMMENDATIONS Proteomics International Laboratories (PIQ) The company’s PromarkerD test can predict future kidney function decline in patients with type 2 diabetes, and with no existing diabetic kidney dise...

Proteomics International Laboratories (PIQ) extends its exclusive distribution agreement for PromarkerD in Great Britain The company added an additional five years to its existing deal with medical diagnostics company Apacor to bring its...

ASX health stocks rise 4.6% this week with positive signs of being back in favour Volpara soars after announcing its first net cash flow positive quarter Morgans basket of healthcare stock picks for 2023 faring well,  all up YTD Healthca...

Japanese startup OUI is on a mission to halve the world’s blindness with its smartphone-based device Which ASX healthcare companies also have smartphone-based products? A quick look at the best and worst ASX healthcare stocks over the past...

ASX health stocks rise 0.8% this week as smaller names in sector show signs of being back in favour Volpara signs five 5-year contracts worth more than US$7.8 million in Total Contract Value Mach 7 continues its 2023 recovery after announc...

The ASX Health sector has fallen ~1.5% in its first trading week of 2023 Mach7  has surged after landing its largest ever customer contract Proteomics gets US approval for PromarkerD test for diabetic kidney disease Healthcare and life sc...

An exclusivity deal for use of Proteomics International Laboratories’ early diabetic kidney disease detection test by Sonic Healthcare USA is close, with the two firms extending a letter of intent.

Aussie shares set to extend gains on Thursday Wall Street pared gains after Fed minutes release China to partially lift ban on Aussie coal   Aussie shares are set to open higher on Thursday, tracking the rally in New York. At 8am AEDT, th...

Proteomics International Laboratories has hit another major milestone with its patented PromarkerD test for diabetic kidney disease receiving US reimbursement code approval from the American Medical Association

Mach7 signs up biggest client in its history Proteomics gets major regulatory approval in the US   ASX medical imaging specialist Mach7 Tech (ASX:M7T) surged 20%  to ~4 month highs on the first trading day of 2023 after landing the larges...

Proteomics International Laboratories (PIQ) receives reimbursement code approval from the American Medical Association for its PromarkerD test The approval refers to a new dedicated CPT proprietary laboratory analyses (PLA) code for the...

Proteomics International Laboratories’ PromarkerD technology is a step closer to a recommendation for clinical use in the UK after being selected for a National Institute for Health and Care Excellence briefing

The ASX is set to track Wall Street higher today US inflation shows signs of slowing down SBF charged by the SEC   The ASX is poised to open higher this morning after wild trading in New York. At 8am AEDT, the ASX 200 Dec futures contract...

ASX Health sector has ended its upward trend falling 0.7% in the past five days in line with broader markets As the end of 2022 approaches several ASX health stocks announce capital raising results to secure funding Healius announces sal...

ASX-listed Proteomics International Laboratories has received patent protection for its PromarkerD diabetic kidney disease test in Hong Kong taking its global coverage of people with diabetes to 64 per cent.

Proteomics International Laboratories (PIQ) secures a patent in Hong Kong for its diabetic kidney test, PromarkerDThe patent is titled ‘Biomarkers associated with pre-diabetes, diabetes and diabetes related conditions’ and is valid until Se...

Cynata gets Notice of Allowance from US Patent Office Proteomics secures patent in Hong Kong Ramsay Healthcare and Avita gave solid quarterly updates Cynata and Proteomics’ patents update Cynata Therapeutics (ASX:CYP) rose 8pc this mornin...

The ASX is set to rally on Friday Wall St had its best one-day move since April 2020 US CPI rose less than expected Local shares are set to surge more than 2% at the open on Friday, tracking the big rally in New York overnight. Wall St ha...

MoneyTalks is Stockhead’s regular drill down into what stocks investors are looking at right now. We’ll tap our extensive list of experts to hear what’s hot, their top picks, and what they’re looking out for. Today we hear from Alto Capital...

ASX-listed Proteomics International Laboratories will increase the capability of its WA Proteomics Facility with a $2 million expansion in partnership with the University of WA and Bioplatforms Australia.

Fitbit has launched a new Device Connect service to give doctors your data Wellnex Life has raised $2.8m to progress its goal to offer OTC medicinal cannabis in Australia Microba expands agreements with Europe’s largest pathology company o...

Proteomics International Laboratories’ (PIQ) first diagnostic test for oesophageal cancer has shown a 90 per cent detection success rateThe test is the company’s latest from its Promarker pipeline and uses biomarkers, or protein “fingerprin...

“Your Stock Request” is a weekly video where we analyse share price charts for stocks on the Australian market (ASX) as requested by you! Email us at [email protected] with your stock request. Limit of one per person, no guarantee o...

Highlights The ASX 200 benchmark index closed lower today (29 August), losing 138.60 points or 1.95% to end at 6,965.50 points. Over the last five days, the index has lost 1.16% and 6.98% over the last 52 weeks. IT was the worst perfo...

Proteomics International Laboratories (PIQ) launches an independent business to commercialise technology for measuring oxidative stress OxiDx is the new incorporated joint venture of Proteomics and the University of Western Australia, and...

Proteomics International (PIQ) receives firm commitments to raise $8 million to advance marketing, sales and further developments of its technology Both new and existing Australian-based institutions, and sophisticated and professional inv...

Recent cap raising suggests biotechs may finally be making a comeback Mesblast annnounced a US$45m cap raise last week Today, Paradigm, Opthea, and Proteomics also announced fund raises Over the past year, the biotech sector has been caug...

ASX 200 and small caps rise circa 1% Regional markets jump on strong leads, US inflation data Ragusa Metals: up 60% Local markets took off at the open, feeling a little of the excitement which took hold of Wall Street overnight. The bench...

Proteomics (PIQ) places its shares in a trading halt pending the release of a capital raising announcement The company will remain in the halt until Monday, August 15, or when the announcement is released, whichever occurs first On August...

Highlights The ASX 200 benchmark index closed up today, gaining 0.13% to end at 7,029.80 points. In last five trading sessions, the benchmark index has gained 0.45%, but is down 5.57% on year-to-date basis. Telecom Services was the be...

Highlights The ASX 200 benchmark index closed up today, gaining 0.13% to end at 7,029.80 points. In last five trading sessions, the benchmark index has gained 0.45%, but is down 5.57% on year-to-date basis. Telecom Services was the be...

Proteomics International Laboratories (PIQ) signs a binding letter of intent to introduce PromarkerD to the United States The contract was signed with Sonic Healthcare USA, regarding entering an exclusive licence for use of the company’s...

The ASX 200 is pretty flat, small caps up circa 0.5%  Materials and energy dragging locally Alibaba reports tonight: analysts predicting 30 thieves, down from previous high of 40   Around lunchtime, the major banks started passing on the...

Proteomics International Laboratories’ (PIQ) PromarkerD test has been ranked by physicians above current standard-of-care tests for predicting diabetic kidney disease The company says the results of a study showing the clinical utility of...